Brian Concannon's holdings at Haemonetics Corporation reflected significant fluctuations over his tenure. At the peak, his vested stock in 2013 alone was valued at approximately $2.47 million. This was part of a larger compensation framework based on performance metrics tied...

Brian Concannon's holdings at Haemonetics Corporation reflected significant fluctuations over his tenure. At the peak, his vested stock in 2013 alone was valued at approximately $2.47 million. This was part of a larger compensation framework based on performance metrics tied to company earnings and revenue, showcasing his alignment with shareholder interests. After a notable high in his stock holdings, they dropped to nominal levels in the years following 2015 due to his resignation. By then, his overall wealth had diverged significantly from his earlier career highs, which points to a broader trend of challenges in equity performance during his later years at the company. While initial years saw strong income and equity growth, Concannon's transition marked a shift where his direct financial stake diminished, emphasizing a curious pattern of wealth tied closely to company fortunes.